[1] Kurtz SM, Ochoa JA, Lau E, et al. Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006[J]. Pacing Clin Electrophysiol, 2010, 33(6): 705-711.
[2] Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction[J]. N Engl J Med, 2008, 359(21):2245-2253.
[3] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J]. N Engl J Med, 2005, 352(3): 225-237.
[4] Voigt A, Shalaby A, Saba S. Continued rise in rates of cardio-vascular implantable device infection in the United States:temporal trends and causative insights[J]. Pacing Clin Electrophysiol, 2010, 33(4): 414-419.
[5] Greenspon AJ, Patel JD, Lau E, et al. Sixteen year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States: 1993-2008 [J]. J Am Coll Cardiol, 2011, 58(10): 1001-1006.
[6] Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management. A scientific statement from the American Heart Association[J]. Circulation, 2010, 121(3): 458-477.
[7] Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections[J]. J Am Coll Cardiol, 2007,49(18): 1851-1859.
[8] Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes[J]. Heart Rhythm, 2010, 7(8): 1043-1047.
[9] 计光, 李玲文, 王霄霞, 等. 经静脉永久心脏起搏器植入前后凝血功能的变化及临床意义[J]. 温州医学院学报, 2007, 37 (3): 212-214.
[10] Sohail MR, Wilson WR, Baddour LM. Infections of nonvalvular cardiovascular devices[M]//Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett Prin-ciples and Practice of Infectious Diseases. Philadelphia:Churchill Livingstone/Elsevier, 2010: 1127-1142.
[11] Osmonov D, Ozcan KS, Erdinler I, et al. Cardiac devicerelated endocarditis: 31-Years experience[J]. J Cardiol, 2013,61(2): 175-180.
[12] Greenspon AJ, Prutkin JM, Sohail MR, et al. Timing of themost recent device procedure influences the clinical outcome of lead-associated endocarditis results of the MEDIC (Multicenter Electrophysiologic Device Infection Cohort) [J]. J Am Coll Cardiol, 2012, 59(7): 681-687.
[13] Dababneh AS, Sohail MR. Cardiovascular implantable electronic device infection: A stepwise approach to diagnosis
and management[J]. Cleve Clin J Med, 2011, 78(8): 529-537.
[14] 王世恒, 邹强, 史燕顺, 等. 凝固酶阴性葡萄球菌耐药性分析[J]. 临床医药实践, 2009,18(9): 681-682.
[15] Vuong C, Otto M. Staphylococcus epidermidis infections[J].Microbes Infect, 2002, 4(4): 481-489.
[16] Klug D, Balde M, Pavin D, et al. PEOPLE Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study [J]. Circulation, 2007, 116(12): 1349-1355.
[17] Raad D, Irani J, Akl EG, et al. Implantable electrophysiologic cardiac device infections: a risk factor analysis[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(11): 3015-3021.
[18] Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry[J]. Heart, 2009, 95(9):715-720.
[19] Uslan DZ, Sohail MR, St Sauver JL, et al. Permanent pace-maker and implantable cardioverter defibrillator infection:a population-based study[J]. Arch Intern Med, 2007, 167 (7): 669-675.
[20] Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients[J]. Am J Kidney Dis, 2007, 49(5): 656-663.
[21] Ipek EG, Guray U, Demirkan B, et al. Infections of implantable cardiac rhythm devices: predisposing factors and outcome[J]. Acta Cardiol, 2012, 67(3): 303-310. |